MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Catalyst Pharmaceuticals Operating Income 2011-2026 | CPRX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Catalyst Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 258 M | 195 M | 86.8 M | 102 M | 52.4 M | 41.3 M | 31.8 M | -35.3 M | -18.7 M | -19.3 M | -20.4 M | -14.6 M | -10.3 M | -5.22 M | -6.08 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 258 M | -35.3 M | 42.5 M |
Quarterly Operating Income Catalyst Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.3 M | 66.3 M | 63.4 M | - | 50.9 M | 54.2 M | 27.1 M | - | -37.2 M | 46.7 M | 35.6 M | - | 25.1 M | 28.6 M | 17.4 M | - | 14 M | 15.8 M | 9.8 M | - | 11.7 M | 10.3 M | 10.7 M | 8.01 M | 13.8 M | 11 M | -988 K | -14.8 M | -8.18 M | -6.34 M | -5.93 M | -5.51 M | -4.31 M | -4.18 M | -4.68 M | -4.31 M | -3.91 M | -4.81 M | -6.24 M | -6.19 M | -5.02 M | -4.9 M | -4.29 M | -3.98 M | -4.11 M | -2.99 M | -3.51 M | -2.71 M | -3.25 M | -2.65 M | -1.71 M | -1.51 M | -1.28 M | -1.07 M | -1.36 M | -2.03 M | -1.13 M | -1.4 M | -1.52 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 66.3 M | -37.2 M | 7.75 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Rigel Pharmaceuticals
RIGL
|
125 M | $ 33.23 | -4.03 % | $ 584 M |  USA |
 |
Graybug Vision
GRAY
|
-23.1 M | - | -11.23 % | $ 9.65 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.15 | -2.68 % | $ 2.54 B | USA |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.72 | -2.75 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-49.6 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 163.7 | -1.61 % | $ 8.14 B | USA |
 |
BridgeBio Pharma
BBIO
|
-523 M | $ 64.66 | -1.37 % | $ 12.4 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-11.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.52 | -2.46 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-102 M | - | - | $ 3.45 B | USA |
 |
Avid Bioservices
CDMO
|
-18.7 M | - | - | $ 789 M | USA |
 |
Certara
CERT
|
21 M | $ 7.16 | 1.49 % | $ 1.15 B | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-22.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
-226 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Capricor Therapeutics
CAPR
|
-24.1 M | $ 25.91 | -3.56 % | $ 694 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-58.5 M | $ 0.99 | -3.28 % | $ 72.7 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-23.4 M | $ 17.75 | -0.79 % | $ 852 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-79.8 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
-12.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-12 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-12 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-211 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
Denali Therapeutics
DNLI
|
-487 M | $ 20.02 | -4.67 % | $ 3.29 B | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Eton Pharmaceuticals
ETON
|
-1.19 M | $ 17.54 | -3.36 % | $ 450 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-52.3 M | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
-17.8 M | - | 7.55 % | $ 38.1 M | USA |